Multiple myeloma trials in Japan
34 trials · From ClinicalTrials.gov, checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 3RecruitingTrial-stage medicine
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Bunkyo-ku, Kagoshima, Kobe, Kofu, Koto, Kyoto, Maebashi, Matsuyama, Okayama, Shibukawa, Shiwa-gun Yahaba-cho, Toyohashi, Yamagata
- Age
- 18 years and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575EU 2023-507871-23-00Registry updated 2026-08-24
Phase 1/2RecruitingTrial-stage medicine
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Where
- Aomori, Chiba, Kanagawa, Osaka, Tokyo, Yamagata
- Age
- 18 years and over
- People
- 123 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05714839EU 2022-501941-63-00Registry updated 2026-08-19
Phase 3RecruitingTrial-stage medicine
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Where
- Fukuoka, Kyoto, Nishinomiya-shi, Okayama, Sapporo, Shibuya-ku, Shinjuku-ku, Suita-shi
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07764978Registry updated 2026-08-14
Phase 4RecruitingTrial-stage medicine
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Where
- Kyoto, Shibuya-ku
- Age
- 18 years and over
- People
- 80 worldwide
- Run by
- Pfizer
See details and how to joinNCT06057402EU 2023-505200-33-00Registry updated 2026-07-01
Phase 1RecruitingTrial-stage medicine
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Bunkyo-ku, Kashiwa-shi, Koto-ku, Kumamoto, Mibu
- Age
- 18 years and over
- People
- 135 worldwide
- Run by
- AbbVie
See details and how to joinNCT06896916EU 2024-512146-41-00Registry updated 2026-05-12
Phase 3RecruitingTrial-stage medicine
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Where
- Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hyōgo, Ibaraki, Ishikawa, Kanagawa, Miyagi, Nara, Numakunai, Osaka, Sapporo, Shibuya-Ku, Suita, Tokyo, Yamagata
- Age
- 18 years and over
- People
- 520 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06679101EU 2024-516030-35-00Registry updated 2026-04-22
Phase 1/2Not yet recruitingTrial-stage medicine
Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
- Where
- Bunkyo-ku, Shibuya-ku, tabashi City
- Age
- 18 years to 70 years
- People
- 17
- Run by
- Nanjing IASO Biotechnology Co., Ltd.
See details and how to joinNCT07510100Registry updated 2026-04-03
Phase 1/2RecruitingTrial-stage medicine
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Where
- Bunkyō City, Bunkyo-ku, Fukuoka, Fukushima, Hokkaido, Isehara-Shi, Kashiwa-shi, Miyagi, Nagasaki, Okayama, Osaka, Yoshida-gun
- Age
- 12 years and over
- People
- 606 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555Registry updated 2026-03-24
No phaseRecruitingResearch participation
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Where
- Kumamoto, Toyokawa
- People
- 50 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06357754Registry updated 2026-01-22
All Multiple myeloma trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.